Cancers of the bowel and hepatobiliary tract

Update on Cancer Therapeutics

Volumn 1, Issue 3, 2006, Pages 353-365

  Draznin, Julia ^a   Sun, Weijing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bevacizumab; Biliary track cancer; Cancer of the large bowel; Capecitabine; Cetuximab; Hepatocellular carcinoma; Irinotecan; Oxaliplatin; Pancreatic cancer

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CAPIRI; CAPOX; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; EXETECAN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; THALIDOMIDE; UFT; UNCLASSIFIED DRUG; XELIRI; XELOX;

ALOPECIA; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG RECEPTOR BINDING; FEBRILE NEUTROPENIA; GALLBLADDER CANCER; HAND FOOT SYNDROME; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; INTESTINE PERFORATION; LIVER CELL CARCINOMA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PANCREAS CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VOMITING;

EID: 33748711298     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.05.003     Document Type: Review

References (131)

1. Jemal A., Murray T., and Ward E. Cancer Statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med 352 5 (2005) 476-487
3. Ries L.A., Wingo P.A., Miller D.S., Howe H.L., Weir H.K., Rosenberg H.M., et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88 May (10) (2000) 2398-2424
4. Macdonald J.S. Adjuvant therapy of colon cancer. CA Cancer J Clin 49 4 (1999) 202-219
5. DeVita Jr. V.T., Hellman S., and Rosenberg S.A. Cancer principles and practice of oncology. 5th ed. (1997), Lippincott-Raven Publishers p. 1144-95
6. American Joint Committee on Cancer. 6th ed.; 2002. p. 113-8.
7. Green F.L., Stewart A.K., and Norton H.J. A new TNM staging strategy for node-positive (stage III) rectal cancer: an analysis of 5,988 patients. Proc Am Soc Clin Oncol 22 (2003) [abstract 1007]
8. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., Mayer R.J., Macdonald J.S., Catalano P.J., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J Clin Oncol 21 15 (2003) 2912-2919
9. Goldberg R.M., Morton R.F., Sargent D.J., Fuchs C., Ramanathan R.K., Williamson S.K., et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil(5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an Intergroup study. Proc Am Soc Clin Oncol 22 (2003) [abstract number 1009]
10. Griffin M.R., Bergstralh E.J., Coffey R.J., Beart Jr. R.W., and Melton III L.J. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 60 November (9) (1987) 2318-2324
11. Minsky B.D., Mies C., Rich T.A., Techt A., and Chaffery J.T. Potentially curative surgery of colon cancer. The influence of blood vessel invasion. J Clin Oncol 6 January (1) (1988) 119-127
12. Wiggers T., Arends J.W., Schutte B., Volovics L., and Bosman F.T. A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61 January (2) (1988) 386-395
13. Krasna M.J., Flancbaum L., Cody R.P., Shneibaum S., and Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61 March (5) (1988) 1018-1023
14. Peethambaram P., Weiss M., Loprinzi C.L., Novotny P., O'Fallon J.R., Erlichman C., et al. An evaluation of postoperative follow-up tests in colon cancer patients treated for cure. Oncology 54 Jul-August (4) (1997) 287-292
15. Pricolo V.E., Finkelstein S.D., Hansen K., Cole B.F., and Bland K.I. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 132 April (4) (1997) 371-375
16. Ahnen D.J., Feigl P., Quan G., Fenoglio-Preiser C., Lovato L.C., Bunn Jr. P.A., et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58 March (6) (1998) 1149-1158
17. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 September (9) (1988) 525-532
18. Ookawa K., Sakamoto M., Hirohshi S., Yoshida Y., Sugimura T., Terada M., et al. Concordant p53 and DCC alterations and allelic losses on chromosome 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer 53 February (3) (1993) 385-387
19. Cho K.R., and Fearon E.R. DCC-linking tumor suppressor genes and altered cell surface interactions in cancer. Curr Opin Genet Dev 5 (1995) 525
20. Jen J., Kim H., Piantadosi S., Liu Z.F., Levitt R.C., Sistonen P., et al. Allelic loss of chromosome 18Q and prognosis in colorectal cancer. N Engl J Med 331 July (4) (1994) 213-221
21. Ogunbiyi O.A., Goodfellow B.J., Herfarth K., Gagliardi G., Swanson P.E., Birnbaum E.H., et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16 February (2) (1998) 427-433
22. Genaurdi M., Viel A., Bonora D., Capozzi E., Bellacosa A., Leonardi F., et al. Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility. Hum Genet 102 January (1) (1998) 15-20
23. Watanabe T., Wu T.T., Catalano P.L., Satriano R., Haller D.G., Benson III A.B., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 April (16) (2001) 1196-1206
24. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., et al. Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 July (3) (2003) 247-257
25. de la Chapelle A. Microsatellite instability. N Engl J Med 349 July (3) (2003) 209-210
26. Sheehan K.M., Sheahan K., O'Donoghue D.P., MacSweeney F., Conroy R.M., Fitzgerald D.J., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282 October (13) (1999) 1254-1257
27. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 June (26) (2000) 1946-1952
28. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 March (10) (2003) 891-899
29. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 March (10) (2003) 883-890
30. Levesque LE, Brophy JM, Zhang B. The risk of myocardial infarction with cyclooxynenase-2 inhibitors: a populations study of elderly adults. Ann Intern Med. Epub Feb 2005.
31. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 8 (2001) 954-959
32. Milas L., Kishi K., Hunter N., Hunter N., Mason K., Masferrer J.L., et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91 September (17) (1999) 1501-1504
33. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6 May (5) (2000) 2006-2011
34. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J Clin Oncol 16 January (1) (1998) 301-308
35. Hoff P.M., Ansari R., Batist G., Cox J., Koscha J., Kuperminc M., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19 April (8) (2001) 2282-2292
36. Michael M., Hedley D., Oza A., Feld R., Pintilie M., Goel R., et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer 2 August (2) (2002) 93-101
37. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 April (7) (2004) 1201-1208
38. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 July (4) (2004) 337-344
39. Rothenberg M.L., Oza A.M., Burger B., Berlin J., Marshall J.L., Ramanathan R.K., et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 22 (2003) a252 [abstract 1011]
40. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355 March (9209) (2000) 1041-1047
41. Saltz L.B., Cox J.V., Blanke C.B., Rosen L.S., Gehrenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 September (13) (2000) 905-914
42. Delaunoit T., Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Findlay B.P., et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101 November (10) (2004) 2170-2176
43. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplain combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
44. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 January (2) (2004) 229-237
45. Cassidy J., Tabernero J., Twelves C., Brunet R., Butts C., Conroy T., et al. XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): post-hoc analysis of a large phase II study. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3555]
46. Welles L., Hochster H., Ramanathan R., Wong L., Hart L., Shpilsky A., et al. Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) ("Tree" study). Proc Am Clin Soc Oncol 22 14S (2004) [abstract no: 3537]
47. Patt YZ, Lin E, Liebman J, Miller W, Lee F, Keiser W, et al. Capecitabine plus irinotecan: a highly active first line treatment for metastatic colorectal cancer (MCRC). GI-ASCO 2004 [abstract 228].
48. Patt Y.Z., Liebmann J., Diamandidis D., Eckhardt S.G., Javle M., Justice G.R., et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a phase II trial. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3602]
49. Park S.H., Bang S.M., Cho E.K., Baek J.H., Oh J.H., Im S.A., et al. First line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 66 5 (2004) 353-357
50. Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for pateitns with metastatic colorectal cancer. J Clin Oncol 22 11 (2004) 2084-2091
51. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 June (23) (2004) 2335-2342
52. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 6 (2003) 669-676
53. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
54. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J., Hecht J., et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3516]
55. http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#avastin
56. Kemeny N., Garay C.A., Gurtler J., Hochster H., Kennedy P., Benson A., et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22 December (23) (2004) 4701-4709
57. Benson A.B., Catalano P.J., Meropol N.J., O'Dwyer P.J., and Giantonio B.J. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E 32000. Proc Am Soc Clin Oncol 22 (2003) [abstract 975]
58. Tabernero J.M., van Cutsem E., Sastre J., Cervantes A., Van Laethem J.L., Humblet Y., et al. An International phase II study of cetuximab in combination with oxaliplatin/5-FU/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR), preliminary results. Proc Am Soc Clin Oncol 23 (2004) 248a
59. Rougier P., Raoul J.L., Van Laethem J.L., Peeters M., Husseini F., Brezault C., et al. Cetuximab + FOLFIRI as first line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3513]
60. Lenz H.J., Mayer R.J., Gold P.L., Mirtsching B., Stella P.J., Cohn A.L., et al. Activity of Cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3510]
61. Hecht J.R., Patnaik A., Malik I., Venook A., Berlin J., Croghan G., et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Clin Soc Oncol 22 14S (2004) [abstract 3511]
62. Buyse M., Zeleniuch-Jaquitte A., and Chalmers T. Adjuvant therapy of colorectal cancer-why we still don't know. JAMA 259 June (24) (1988) 3571-3578
63. Laurie J.A., Moertel C.G., Fleming T.R., Wieand H.S., Leigh J.E., Rubin J., et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-fluorouracil. The North Central Cancer Treatment Group and Mayo Clinic. J Clin Oncol 7 October (10) (1989) 1447-1456
64. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122 March (5) (1995) 321-326
65. Rustum Y.M., Cao S., and Zhang Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cancer J Sci Am 4 January-February (1) (1998) 12-18
66. Wolmark N., Rockette H., Fisher B., Wicherham D.L., Redmond C., Fisher E.R., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 11 October (10) (1993) 1879-1887
67. Haller D.G., Catalano P.J., Macdonald J.S., and Mayer R.J. Fluorouracil, leucovorin and levaminsole adjuvant therapy for colon cancer: Five-year report of INT-0089. Proc Am Soc Clin Oncol 17 (1998) 265a [abstract 982]
68. Andre T., Boni C., Mounedji-Boudaif L., Navarro M., Tabernero J., Hickish T., et al. Tabah-Fisch I, de Gramont A, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 June (23) (2004) 2343-2351
69. Sargent D.J., Wieand S., Benedetti J., Labianca R., Haller D.G., Shepherd L.E., et al. Disease-free survival vs. overall survival as primary end point adjuvant colon cancer studies: individual patients data from 12,915 patients on 15 randomized trials. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3502]
70. http://en.sanofi-aventis.com/images/44_24731.pdf, accessed on November 14, 2004
71. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology available on the Web. http://www.nccn.org/processionals/physician_gls/default.asp
72. Saltz L.B., Niedzwiecki D., Hollis D., Goldberg R.M., Hantel A., Thomas J.P., et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin (FL) alone in stage III colon cancer (Intergroup trial CALGB C89803). Proc Am Clin Oncol 22 14S (2004) [abstract 3500]
73. Sakamoto J., Ohashi Y., Hamada C., Buyse M., Burzykowski T., and Piedbois P. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22 February (3) (2004) 484-492
74. Cassidy J., Scheithauer W., McKendrik J., Kroning H., Nowacki M.P., Seitz J.F., et al. Capecitabine vs. bolus 5-FU/Leucovorin as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3509]
75. Wolmark N., Wieand S., Lembersky B., Colangelo L., Smith R., and Pazdur R. A phase III trial comparing oral UFT in stage II and III carcinoma of the colon: results of NSABP protocol C-06. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3508]
76. Marsoni. S for IMPACT investigators: efficacy of adjuvant fluorouracil and leucovorin in Stage B2 and C colon cancer. Semin Oncol 28 Suppl. 1 (2001) 14-19
77. Gill S., Loprinzi C.L., Sargent D.J., Throme S.D., Alberts S.R., Haller D.G., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by now much?. J Clin Oncol 22 May (10) (2004) 1797-1806
78. Benson A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 August (16) (2004) 3408-3419
79. Figuereo A., Charett M.L., Maroun J., Brouwers M.C., and Zuraw L. Adjuvant therapy for stage II colon cancer: a systemic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 August (16) (2004) 3395-3407
80. Gray R.G., Barnwell J., Hills R., McConkey C., Williams N., and Kerr D. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol 22 14s (2004) [abstract 3501]
81. Carethers J.M., Smith E.J., Behling C.A., Nguyen L., Tajima A., Doctolero R.T., et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 February (2) (2004) 394-401
82. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 February (3) (2004) 529-536
83. Wang Y., Jatkoe T., Zhang Y., Mutch M.G., Talantov D., Jiang J., et al. Gene expressionprofiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22 May (9) (2004) 1564-1571
84. Martenson J.A., Willett C.G., Sargent D.J., Mailliard J.A., Donohue J.H., Gunderson L.L., et al. Phase III study of adjuvant chemotheraoy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of Intergroup protocol 0130. J Clin Oncol 22 August (16) (2004) 3277-3283
85. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., and El-Serag H.B. Hepatitis C infection and increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 November (5) (2004) 1372-1380
86. Yu M.W., and Chen C.J. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 17 October (2) (1994) 71-91
87. Pichlmayr R., Weimann A., and Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 20 (July 1994) 33S-40S
88. Kamath P.S., Wiesner R.H., Malinchoc M., Kremers W., Therneau T.M., Kosberg C.L., et al. A model to predict survival in patients with end-stage live disease. Hepatology 33 February (2) (2001) 464-470
89. Sharma P., Balan V., Hernandez J.L., Harper A.M., Edwards E.B., Rodriguez-Luna H., et al. Liver Transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 10 January (1) (2004) 36-41
90. Tanabe K.K., Curley S.A., Dodd G.D., Siperstein A.E., and Goldberg S.N. Radiofrequency ablation: the experts weigh in. Cancer 100 February (3) (2004) 641-650
91. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., and Chen Y.C. radiofrequency ablation improves prognosis compared with ethanol injection for hepatocelllar carcinoma
92. Carr B.I. Advanced, unresectable hepatocellular carcinoma (HCC): responses and long term survival after 90Yttrium microspheres (Therasphere) treatment in 80 patients. Proc Am Soc Clin Oncol 23 (2004) 334s
93. Geschwind J.F., Salem R., Carr B.I., Soulen M.C., Thurston K.G., Goin K.A., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 November (5 Suppl. 1) (2004) S194-S205
94. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al., Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359 May (9319) (2002) 1734-1739
95. Patt Y.A., Hassan M.M., Aguayo A., Nooka A.K., Lozano R.D., Curley S.A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101 August (3) (2004) 578-586
96. Leung T.W., Patt Y.Z., lau W.Y., Ho S.K., Yu S.C., Chan A.T., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5 7 (1999) 1676-1681
97. Yeo W., Zee B., Leung W.T., Lau W.Y., Mok T.S.K., Wong H.T.M., et al. Phase III study of doxorubicin (A) versus cisplatin (P)/interferon alpha-2b (I)/doxorubicin (A)/fluorouracil (F) for inoperable hepatocellular carcinoma. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4026]
98. Yen Y., Doroshow J., Lelong L., Lim D., Wagman L., Morgan R., et al. Phase II study of oxaliplatin inpatients with unresectable, metastatic or recurrent hepatocellular cancer. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4169]
99. Boige V., Taieb J., Hebbar M., Magherini E., Mignard D., Debaere T., et al. Final results of a multicenter phase II study of irinotecan (CPT-11) in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4180]
100. Kim G.P., Alberts S.R., Tscgetter L.K., Fitch T.R., Dakhil S.R., Morlan B.W., et al. Gemcitabine and docetaxel in patients with measurable unresectable of metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatmetn Groups (NCCTG) phase II trial. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4270]
101. Taieb J., Mansourbakht T., Ducreux M., Bonyhay L., De Baere T., Delgado M., et al. Gemciabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC): results of a phase II study. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4086]
102. Hsu C., Chen L.T., Lai M.Y., Yeh K.H., Lee P.H., and Cheng A.L. Comparison of anti-tumor activity of thalidomide between hepatitis B (HBV) and hepatitis C (HCV) related hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 14S (2004) [abstract 4198]
103. Schwartz J.D., Schwartz M., Goldman J., Lehrer D., Coll D., Kinkabwala M., et al. Bevacizumab in hepatocellular carcinoma patients without metastasis and without invasion of the portal vein. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4088]
104. Philip P.A., Mahoney M., Thomas J., Pitot H., Donehower R., Kim G., et al. Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4025]
105. Richly H., Kupsch P., Passarge K., Grubert M., Hilger R.A., Haase C.G., et al. Results of a phase I trial of BAY 43-90006 in combination with doxorubicin in patients with refractory solid tumors. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3049]
106. Nehls O., Oettle H., Hartmann J.T., Hofheinz R., Hochhaus A., Makowski M., et al. A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas. Proc Am Soc Clin Oncol 23 336s (2004) [abstract 4091]
107. Andre T., Tournigand C., Rosmorduc O., Provent S., Maindrault-Goebel F., Avenin D., et al. Gemcitabine combined with oxaliplain (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15 September (9) (2004) 1339-1343
108. Kornek G.V., Schuell B., Laengle F., Gruenberger T., Penz M., Karall K., et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial. Ann Oncol 15 March (3) (2004) 478-483
109. Doval D.C., Sekhon J.S., Gupta S.K., Fuloria J., Shukla V.K., Gupta S., et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naïve, unresectable gall bladder cancer. Br J Cancer 90 April (8) (2004) 1516-1520
110. Ahmed S., Bhargava A., and Mehrotra B. Efficacy of gemcitabine in advanced unresectable biliary tract cancers. Proc Am Soc Clin Oncol (2004) [GI, abstract number 97]
111. Knox J.J., Hedley D., Oza A.M., Siu L., Feld R., Chen E., et al. Phase II trial of gemcitabine plus capecitabine (GemCap) in patients with advanced or metastatic biliary tract cancer. Proc Am Soc Clin Oncol (2004) [GI, abstract number 101]
112. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer Statistics 2004. CA Cancer J Clin 54 January-February (1) (2004) 8-29
113. Trende M., Schwall G., and Saeger H.D. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 211 April (4) (1990) 447-458
114. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., et al. A randomized trial of chemorathiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 March (12) (2004) 1200-1210
115. Wilkowski R., Thoma M., Duhmke E., Rau H.G., and Heinemann V. Concurrent chemotheradiotherapy with gemcitabine and cisplain after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Biol Phys 58 March (3) (2004) 768-772
116. Nukui Y., Picozzi V.J., and Traverso W. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 179 (2000) 367-371
117. Picozzi V.J., Kozarek P.A., and Traverso L.W. Interferon based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcimona. J Surg 185 (2003) 476-480
118. Ben-Josef E., Showlds A.F., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiation Oncology Biol Phys 59 (2004) 454-459
119. Van Rijswijk R.E., Jeziorski K., Wagener D.J., Van Laethem J.L., Reuse S., Baron B., et al. Weekly high dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 40 September (14) (2004) 2077-2081
120. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinic benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15 June (6) (1997) 2403-2413
121. Tempero M., Plunkett W., Van Haperen V.R., Hainsworth J., Hochster H., Tenato L., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol September (18) (2003) 3402-3408
122. Viret F., Ychou M., Lepille D., Mineur L., Navarro F., Topart D., et al. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4118]
123. Reni M., Cordio S., Passardi A., Panucci M.G., Passoni P., Oliani C., et al. Final results of phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic ademocarcinoma. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4010]
124. Kulke M.H., Niedzwiecki D., Tempero M.A., Hollis D.R., and Mayer R.J. A randomized phase II study of gemcitabine/cisplain, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel. Or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CLAGB 89904). Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4011]
125. Louvet C., Labianca R., Hammel P., Lledo G., De Braud F., Andre T., et al. GemOx (gemcitabine and oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4008]
126. Cheverton P., Friess H., Andras C., Salek T., Geddes C., Bodoky G., et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4005]
127. Richards D.A., Kindler H.L., Oettle H., Ramanathan R., Van Laethem L.J., Peeters M., et al. A randomized phase III study comparing gemcitabine + pemetrexed verus gemcitabine in patients with locally advanced and metastatic pancreas caner. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4007]
128. Kindler H.L., Friberg G., Stadler W.M., Singh D., Locker G., Nattam S., et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium. Proc Am Soc Clin Oncol (2004) [GI, abstract 86]
129. Ebert M., Nitsche B., Roecken C., Fahlke J., Hosius C., Gschaidmeier H., et al. A prospective and randomized clinical trial of the tyrosine kinase inhibitor imatinib mesylate as an intial therapy of advanced pancreatic caner. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4151]
130. Maples W.J., Stevenson J., Sumrall S.V., Naughton M., Kauh J., and Schwartz J. Advanced Pancreatic Cancer: a multi-institutional trial with gemcitabine and thalidomide. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 4082]
131. Richly H., Kupsch K., Passarge K., Grubert M., Hilger R.A., Haase C.G., et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors. Proc Am Soc Clin Oncol 22 14S (2004) [abstract 3049]